According to the literature review, treatment with [177Lu]Lu-PSMA has a positive impact on prostate-specific antigen (PSA) within the first cycle and a negative impact on lymph node metastasis. Here, KLK3 is linked to metastatic malignant neoplasm in the lymph nodes.